2574-42-7

Basic information

• Product Name: {bicyclo[2.2.2]octan-1-yl}methanol
• Synonyms: {bicyclo[2.2.2]octan-1-yl}methanol;bicyclo[2.2.2]octane-1-methanol;Bicyclo[2.2.2]oct-1-yl-methanol
• CAS NO: 2574-42-7
• Molecular Formula: C₉H₁₆O
• Molecular Weight: 140.22
• Mol File: 2574-42-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 61.5-62 °C
• Boiling Point: 100 °C(Press: 10 Torr)
• Appearance: /
• Density: 1.028±0.06 g/cm3(Predicted)
• PKA: 15.24±0.10(Predicted)
• CAS DataBase Reference: {bicyclo[2.2.2]octan-1-yl}methanol(CAS DataBase Reference)
• NIST Chemistry Reference: {bicyclo[2.2.2]octan-1-yl}methanol(2574-42-7)
• EPA Substance Registry System: {bicyclo[2.2.2]octan-1-yl}methanol(2574-42-7)

Safety Data

• Hazardous Substances Data: 2574-42-7(Hazardous Substances Data)

Usage

General Description

Bicyclo[2.2.2]octan-1-yl methanol, also known as the Endo-methanohydrophenanthrene, is a chemical compound with a bicyclic structure. It is a colorless liquid with a slightly sweet odor, and is commonly used in the fragrance and flavor industry. This chemical is mainly used as a fragrance ingredient in personal care products, perfumes, and household items. It can also be used as a flavoring agent in food and beverages. Bicyclo[2.2.2]octan-1-yl methanol is known for its ability to provide a fresh and clean scent, and is often used in combination with other fragrance ingredients to enhance the overall scent profile of a product. Additionally, it has been found to have potential applications in the pharmaceutical and medical fields.

Upstream product

• 31818-12-9 ethyl bicyclo[2.2.2]octane-1-carboxylate 
• 2064-04-2 Bicyclo<2.2.2>octan-1-carbonsaeure-methylester 
• 110371-29-4 methyl 4-(carbonochloridoyl)bicyclo[2.2.2]octane-1-carboxylate 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 3048-85-9 1-Aethoxycarbonyl-bicyclo<2.2.2>octan-2,3-dicarbonsaeure 
• 3037-84-1 ethyl bicyclo[2.2.2]oct-2-ene-1-carboxylate 
• 15023-45-7 methyl exo-2-bromobicyclo<2.2.1>heptane-1-carboxylate 
• 2534-90-9 exo-2-bromobicyclo<2.2.1>heptane-1-carboxylic acid 
• 85173-54-2 exo-2-bromobicyclo<2.2.1>heptane-1-carboxylic acid chloride 
• 18720-30-4 norbornane-1-carboxylic acid 
• 2064-02-0 1-(Hydroxymethyl)bicyclo<2.2.1>heptane 
• 2287-57-2 methyl bicyclo<2.2.1>heptane-1-carboxylate 
• 88412-20-8 Bicyclo<2.2.2>octane-1,4-dimethanol Bis(p-toluene-sulfonate) 
• 699-55-8 bicyclo[2.2.2]octane-1-carboxylic acid 

Downstream Products

• 7363-97-5 bicyclo<2.2.2>octane-1-carboxaldehyde tosylhydrazone 
• 96454-73-8 1-ethynylbicyclo<2.2.2>octane 
• 2064-05-3 bicyclo<2.2.2>octane-1-carboxaldehyde 
• 699-55-8 bicyclo[2.2.2]octane-1-carboxylic acid 
• 2346-03-4 (bicyclo<2.2.2>oct-1-yl)methyl tosylate 
• 269069-78-5 5-{[5-(Adamantan-1-yloxymethyl)-2-bicyclo[2.2.2]oct-1-yl-1H-imidazole-4-carbonyl]-amino}-2-fluoro-benzoic Acid 
• 269069-68-3 5-{[5-(2-Adamantan-1-yl-ethyl)-2-bicyclo[2.2.2]oct-1-yl-1H-imidazole-4-carbonyl]-amino}-2-fluoro-benzoic Acid 
• 110977-40-7 1-hydroxybicyclo<3.2.2>non-2-yl benzoate 

Relevant articles and documents

MITOCHONDRIA-TARGETING PEPTIDES

Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

Controlled Reduction of Carboxamides to Alcohols or Amines by Zinc Hydrides

New protocols for controlled reduction of carboxamides to either alcohols or amines were established using a combination of sodium hydride (NaH) and zinc halides (ZnX2). Use of a different halide on ZnX2 dictates the selectivity, wherein the NaH-ZnI2 system delivers alcohols and NaH-ZnCl2 gives amines. Extensive mechanistic studies by experimental and theoretical approaches imply that polymeric zinc hydride (ZnH2)∞ is responsible for alcohol formation, whereas dimeric zinc chloride hydride (H?Zn?Cl)2 is the key species for the production of amines.

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.